Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22097553 | 0.83 | IDO1 (0.33) | GABRA1GABRB1GABRB2CYP3A4CYP2D6 | |
| SCHEMBL12974095 | 0.83 | GABRA1 (0.46) | GABRA1GABRB1GABRB2CYP3A4SLC6A2 | |
| SCHEMBL27822371 | 0.79 | GABRA1 (0.34) | GABRA1GABRB1GABRB2CYP3A4CYP2D6 | |
| SCHEMBL1125463 | 0.78 | TP53 (0.47) | PDE2AGABRA1GABRB1CYP3A4KCNH2 | |
| SCHEMBL17946909 | 0.78 | TP53 (0.47) | PDE2AGABRA1GABRB1CYP3A4KCNH2 | |
| SCHEMBL30806659 | 0.78 | TP53 (0.47) | PDE2AGABRA1GABRB1CYP3A4KCNH2 | |
| SCHEMBL16618296 | 0.78 | TP53 (0.47) | PDE2AGABRA1GABRB1CYP3A4KCNH2 | |
| SCHEMBL3795214 | 0.78 | IDO1 (0.34) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23489650 | 0.77 | PDE2A (0.47) | PDE2ASLC6A4KCNH2ADRB2ADRB1 | |
| SCHEMBL17216071 | 0.77 | PDE2A (0.47) | PDE2ASLC6A4KCNH2ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326029-A1 | NON-CYCLIC SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-12-31 | — | — | US | disclosed |
| US-20090326029-A1 | NON-CYCLIC SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-12-31 | — | — | US | disclosed |
| US-20090326029-A1 | NON-CYCLIC SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-12-31 | — | — | US | disclosed |
| EP-2032564-A2 | SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007143506-A2 | SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326029-A1 | NON-CYCLIC SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | CYP3A4, CYP2C8, ABCB1 | PDE2A 947/4885GABRA1 1314/4885GABRB1 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.